Iwai, Yoshiko
Nippon Medical School,
Japan
2024 Rank: 166382
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Arthritis & Rheumatology
Rank in SubField 1: 3132 out of 157372 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 166382 | 192194 |
| Total Cites | 872 | 886 |
| H-index | 10 | 10 |
| Hm-index | 2 | 2 |
| Number of Single Authored Papers | 4 | 4 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 10 | 10 |
| Total Cites to Single+First Authored Papers | 273 | 277 |
| Number of Single+First+Last Authored Papers | 13 | 13 |
| Total Cites to Single+First+Last Authored Papers | 301 | 305 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 724 | 730 |
| Ratio of Total Citations to Distinct Citing Papers | 1.20 | 1.21 |
| Self-Citation Percentage |
1.58%
|
|
Iwai, Yoshiko
Graduate School of Medicine,
Japan
2023 Rank: 135491
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Arthritis & Rheumatology
Rank in SubField 1: 2774 out of 147556 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 135491 | 157244 |
| Total Cites | 1034 | 1054 |
| H-index | 10 | 10 |
| Hm-index | 3 | 3 |
| Number of Single Authored Papers | 3 | 3 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 9 | 9 |
| Total Cites to Single+First Authored Papers | 365 | 370 |
| Number of Single+First+Last Authored Papers | 12 | 12 |
| Total Cites to Single+First+Last Authored Papers | 380 | 385 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 843 | 853 |
| Ratio of Total Citations to Distinct Citing Papers | 1.23 | 1.24 |
| Self-Citation Percentage |
1.90%
|
|
Iwai, Yoshiko
Nippon Medical School,
Japan
2022 Rank: 100961
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Arthritis & Rheumatology
Rank in SubField 1: 2362 out of 138599 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 100961 | 118011 |
| Total Cites | 1204 | 1232 |
| H-index | 12 | 12 |
| Hm-index | 3 | 3 |
| Number of Single Authored Papers | 2 | 2 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 8 | 8 |
| Total Cites to Single+First Authored Papers | 396 | 402 |
| Number of Single+First+Last Authored Papers | 11 | 11 |
| Total Cites to Single+First+Last Authored Papers | 421 | 427 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 968 | 983 |
| Ratio of Total Citations to Distinct Citing Papers | 1.24 | 1.25 |
| Self-Citation Percentage |
2.27%
|
|
Iwai, Yoshiko
Nippon Medical School,
Japan
2020 Rank: 97937
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Arthritis & Rheumatology
Rank in SubField 1: 1997 out of 108509 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 97937 | 111725 |
| Total Cites | 1435 | 1485 |
| H-index | 13 | 13 |
| Hm-index | 2 | 3 |
| Number of Single Authored Papers | 3 | 3 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 9 | 9 |
| Total Cites to Single+First Authored Papers | 464 | 476 |
| Number of Single+First+Last Authored Papers | 12 | 12 |
| Total Cites to Single+First+Last Authored Papers | 486 | 498 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 1088 | 1117 |
| Ratio of Total Citations to Distinct Citing Papers | 1.32 | 1.33 |
| Self-Citation Percentage |
3.37%
|
|
Related Profiles
Featured Profiles
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.